Kestra Advisory Services LLC Boosts Position in Pfizer Inc. $PFE

Kestra Advisory Services LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 14.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,954,595 shares of the biopharmaceutical company’s stock after buying an additional 249,309 shares during the period. Kestra Advisory Services LLC’s holdings in Pfizer were worth $54,885,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in the stock. Mackenzie Financial Corp grew its holdings in Pfizer by 119.6% during the 3rd quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company’s stock worth $79,157,000 after acquiring an additional 1,691,773 shares in the last quarter. Penn Davis Mcfarland Inc. increased its position in Pfizer by 50.9% during the 4th quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock valued at $4,266,000 after purchasing an additional 57,777 shares during the period. Ameriprise Financial Inc. raised its holdings in shares of Pfizer by 48.2% in the 3rd quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock valued at $468,174,000 after purchasing an additional 5,978,927 shares in the last quarter. Danske Bank A S bought a new stake in shares of Pfizer in the 3rd quarter valued at about $81,298,000. Finally, Vanguard Group Inc. lifted its position in shares of Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after purchasing an additional 7,031,162 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on PFE shares. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Guggenheim upped their target price on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 target price on shares of Pfizer in a research report on Thursday, May 14th. Citigroup lifted their price target on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. Finally, Morgan Stanley upped their price objective on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.56.

Pfizer Stock Up 0.7%

NYSE:PFE opened at $24.22 on Friday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a twelve month low of $23.11 and a twelve month high of $28.75. The company has a market cap of $138.02 billion, a PE ratio of 18.49 and a beta of 0.35. The company’s 50 day moving average is $25.41 and its two-hundred day moving average is $26.20.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the company posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. Pfizer’s payout ratio is currently 131.30%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer shares benefited as AstraZeneca’s failed Phase 3 trial in a rare heart disease pushed investors toward rival drugmakers, including PFE. Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump
• Positive Sentiment: Pfizer’s oncology franchise got some attention after reports suggesting recent FDA action on IBRANCE could improve the investment case for the company’s cancer portfolio. Did FDA’s IBRANCE Maintenance Approval Just Shift Pfizer’s (PFE) Oncology-Focused Investment Narrative?
• Positive Sentiment: Pfizer also highlighted ongoing pipeline work, including a Phase 1 bioavailability study and its MUST multiple myeloma study, reinforcing the company’s longer-term R&D pipeline narrative. Pfizer Refines Early-Stage Drug Formulations With New Phase 1 Bioavailability Study Pfizer’s MUST Study Offers Fresh Insight Into Tough?to?Treat Multiple Myeloma
• Neutral Sentiment: J.P. Morgan lowered its price target on Pfizer and kept a Neutral rating, which signals continued caution even though the firm still sees some upside from current levels. Pfizer (PFE) Receives a Hold from J.P. Morgan
• Neutral Sentiment: Additional headlines around Pfizer’s dividend appeal, valuation, and analyst commentary are likely reinforcing investor debate, but they do not point to a major fundamental shift by themselves. Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
• Negative Sentiment: Jim Cramer declined to recommend Pfizer despite its high dividend yield, reflecting ongoing skepticism about the stock’s near-term appeal. ‘It Kills Me to Say That’: Cramer Won’t Recommend Pfizer, Even With Its 7% Dividend

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.